









市场行情
/
股票
/
nasdaq-aytu
/

Aytu Biopharma Inc

AYTU

2.550USD

+0.080+3.24%

收盘 12/19, 16:00（美东）报价延迟15分钟

25.28M总市值

亏损市盈率 TTM



Aytu Biopharma Inc

2.550

+0.080+3.24%

概览公司财务分析

概览

公司

财务

分析

关于 Aytu Biopharma Inc 公司

Aytu BioPharma, Inc. is a pharmaceutical company focused on commercializing novel therapeutics. The Company's business is focused on its prescription pharmaceutical products sold primarily through third party wholesalers and pharmacies and which primarily consists of two product portfolios. The first consists of two products for the treatment of ADHD: Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets. The second consists primarily of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency.

Aytu Biopharma Inc简介



公司代码AYTU

公司名称Aytu Biopharma Inc

上市日期Oct 20, 2017

CEODisbrow (Joshua R)

员工数量82

证券类型Ordinary Share

年结日Oct 20

公司地址7900 E. Union Avenue

城市DENVER

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编80237

电话17204376580

网址https://aytubio.com/

公司代码AYTU

上市日期Oct 20, 2017

CEODisbrow (Joshua R)

Aytu Biopharma Inc公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Jarrett T. (Josh) Disbrow

Chief Business Officer

61.57K

+108.97%

Mr. Ryan J. Selhorn, CPA

Chief Financial Officer, Treasurer, Corporate Secretary

49.74K

+210.89%

Mr. Greg Pyszczymuka

Chief Commercial Officer

36.10K

+51.62%

Mr. Carl C. Dockery

Independent Director

21.15K

+89.67%

Ms. Vivian H. Liu

Independent Director

19.82K

+101.78%

Mr. Abhinav (Abi) Jian

Independent Director

Mr. John A. Donofrio, Jr.

Independent Chairman of the Board

Mr. Joshua R. (Josh) Disbrow

Chief Executive Officer, Director

名称

名称/职务

职务

持股

持股变动

Mr. Jarrett T. (Josh) Disbrow

Chief Business Officer

61.57K

+108.97%

Mr. Ryan J. Selhorn, CPA

Chief Financial Officer, Treasurer, Corporate Secretary

49.74K

+210.89%

Mr. Greg Pyszczymuka

Chief Commercial Officer

36.10K

+51.62%

Mr. Carl C. Dockery

Independent Director

21.15K

+89.67%

Ms. Vivian H. Liu

Independent Director

19.82K

+101.78%

Mr. Abhinav (Abi) Jian

Independent Director

收入明细

单位: USD更新时间: 10月6日周一

FY2025

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2021

FY2020

FY2019

业务USD

名称

营收

占比

ADHD portfolio

57.58M

86.73%

Pediatric portfolio

8.77M

13.21%

Other

37.00K

0.06%

由于公司未披露，未能获取相关数据

业务

地区

业务USD

名称

营收

占比

ADHD portfolio

57.58M

86.73%

Pediatric portfolio

8.77M

13.21%

Other

37.00K

0.06%

股东统计

更新时间: 12月17日周三

持股股东

股东类型

持股股东

占比

Nantahala Capital Management, LLC

10.67%

Stonepine Capital Management, LLC

8.75%

AWM Investment Company, Inc.

6.08%

The Vanguard Group, Inc.

2.73%

Diadema Partners LP

2.68%

其他

69.09%

持股股东

占比

Nantahala Capital Management, LLC

10.67%

Stonepine Capital Management, LLC

8.75%

AWM Investment Company, Inc.

6.08%

The Vanguard Group, Inc.

2.73%

Diadema Partners LP

2.68%

其他

69.09%

股东类型

持股股东

占比

Hedge Fund

16.00%

Investment Advisor/Hedge Fund

15.97%

Individual Investor

5.41%

Investment Advisor

3.17%

Bank and Trust

0.03%

其他

59.43%

机构持股



更新时间: 12月8日周一

报告期

机构数

持股数

持股占比

持股变动

2025Q4

3.62M

34.64%

2025Q3

3.62M

35.61%

+200.00K

2025Q2

3.42M

23.61%

+1.37M

2025Q1

1.88M

32.85%

-147.25K

2024Q4

1.88M

35.64%

-167.56K

2024Q3

2.05M

38.87%

-5.48K

2024Q2

2.06M

35.52%

+258.31K

2024Q1

1.80M

39.85%

-420.62K

2023Q4

1.77M

40.04%

+44.24K

2023Q3

1.73M

39.72%

+20.75K

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Nantahala Capital Management, LLC

1.09M

10.96%

Jun 30, 2025

Stonepine Capital Management, LLC

812.68K

8.2%

+348.95K

+75.25%

Jun 30, 2025

AWM Investment Company, Inc.

619.87K

6.25%

+619.87K

Jun 30, 2025

The Vanguard Group, Inc.

27.89K

0.28%

Jun 30, 2025

Disbrow (Joshua R.)

153.26K

1.71%

+66.67K

+76.99%

Jun 09, 2025

Lytton (Laurence W)

506.61K

5.11%

+506.61K

Jun 09, 2025

Two Sigma Investments, LP

35.03K

0.35%

+35.03K

Jun 30, 2025

Renaissance Technologies LLC

89.91K

0.91%

+13.09K

+17.04%

Jun 30, 2025

Geode Capital Management, L.L.C.

53.87K

0.54%

-75.00

-0.14%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

Dimensional US Core Equity 1 ETF

DFA Dimensional US Sustainability Core 1 ETF

Dimensional US Core Equity 1 ETF

占比0%

DFA Dimensional US Sustainability Core 1 ETF

占比0%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

Jan 05, 2023

Merger

20→1

Jan 05, 2023

Merger

20→1

Jan 05, 2023

Merger

20→1

Jan 05, 2023

Merger

20→1

Dec 08, 2020

Merger

10→1

Dec 08, 2020

Merger

10→1

公告日期

类型

比率

Jan 05, 2023

Merger

20→1

Jan 05, 2023

Merger

20→1

Jan 05, 2023

Merger

20→1

Jan 05, 2023

Merger

20→1

Dec 08, 2020

Merger

10→1

Dec 08, 2020

Merger

10→1

Dec 08, 2020

Merger

10→1

Dec 08, 2020

Merger

10→1

常见问题

Aytu Biopharma Inc的前五大股东是谁？



Aytu Biopharma Inc 的前五大股东如下：
Nantahala Capital Management, LLC持有股份：1.09M，占总股份比例：10.96%。
Stonepine Capital Management, LLC持有股份：812.68K，占总股份比例：8.20%。
AWM Investment Company, Inc.持有股份：619.87K，占总股份比例：6.25%。
The Vanguard Group, Inc.持有股份：27.89K，占总股份比例：0.28%。
Disbrow (Joshua R.)持有股份：153.26K，占总股份比例：1.71%。